User login
Current, short-term use of hormone replacement therapy led to a 43% increase in risk of serous and endometrioid ovarian cancers, according to a large meta-analysis reported online in the Lancet.
Risk fell after women stopped hormone replacement therapy (HRT), but “remained appreciable” for the next few years, wrote the Collaborative Group on Epidemiological Studies of Ovarian Cancer. And long-term users had an estimated 25% increase in ovarian cancer risk, even a full decade after stopping HRT (relative risk, 1.25; 95% confidence interval, 1.07 to 1.46; P = .005), the group reported.
The findings “strongly suggest a causal relationship – i.e., that among otherwise similar women, use of hormone therapy increases the probability of developing the two most common types of ovarian cancer,” the group wrote (Lancet 2015 Feb. 13 [doi: 10.1016/ S0140-6736(14)61687-1]).
Guidelines on HRT from the United States and Europe do not mention ovarian cancer, and those from the United Kingdom describe only risk with long-term use. The findings are “directly relevant to medical advice, personal choices, and the current efforts to revise ... guidelines,” the investigators wrote.
The meta-analysis included 52 observational cohort studies, 17 of which were prospective. In all, 12,110 postmenopausal women in the prospective studies developed ovarian cancer, and 55% had used HRT. Women who had been on HRT for less than 5 years were 1.43 times more likely to develop ovarian cancer than were nonusers (RR, 1.43; 95% CI, 1.29 to 1.46; P < .0001). Thus, HRT might cause one extra case of ovarian cancer per 1,000 users, and one extra death from ovarian cancer per 1,700 users, the group wrote.
Risk of ovarian cancer was similar regardless of age and type of HRT use, the investigators said.
The Medical Research Council and Cancer Research UK funded the analysis. The authors declared no relevant financial conflicts of interest.
The findings support adding ovarian cancer to the list of adverse effects associated with hormone therapy use. However, compared with cardiovascular diseases and breast cancer, ovarian cancer is far less common, suggesting that overall risk assessment of hormone therapy will not be strongly affected by these results.
The present study did not evaluate dose, and median year of diagnosis was 2001 — slightly before the widespread change in use patterns occurred with publication of the Women’s Health Initiative findings.
It is still not clear whether the current recommendation to use hormone therapy for the shortest duration possible is appropriate for women who are concerned about an increased risk of ovarian cancer. The current report underlines the importance and limitations of observational data for rare and long-term outcomes, especially for the complex associations between regimen, dose, duration, route of administration, and timing of hormone therapy use with ovarian, breast, and endometrial cancers.
Dr. Nicolas Wentzensen and Dr. Britton Trabert are investigators with the division of cancer epidemiology & genetics at the National Cancer Institute, Bethesda, Md. These comments are taken from their accompanying editorial (Lancet 2015 Feb. 13 [doi:10.1016/ S0140-6736(14)62458-2]). They had no competing interests.
The findings support adding ovarian cancer to the list of adverse effects associated with hormone therapy use. However, compared with cardiovascular diseases and breast cancer, ovarian cancer is far less common, suggesting that overall risk assessment of hormone therapy will not be strongly affected by these results.
The present study did not evaluate dose, and median year of diagnosis was 2001 — slightly before the widespread change in use patterns occurred with publication of the Women’s Health Initiative findings.
It is still not clear whether the current recommendation to use hormone therapy for the shortest duration possible is appropriate for women who are concerned about an increased risk of ovarian cancer. The current report underlines the importance and limitations of observational data for rare and long-term outcomes, especially for the complex associations between regimen, dose, duration, route of administration, and timing of hormone therapy use with ovarian, breast, and endometrial cancers.
Dr. Nicolas Wentzensen and Dr. Britton Trabert are investigators with the division of cancer epidemiology & genetics at the National Cancer Institute, Bethesda, Md. These comments are taken from their accompanying editorial (Lancet 2015 Feb. 13 [doi:10.1016/ S0140-6736(14)62458-2]). They had no competing interests.
The findings support adding ovarian cancer to the list of adverse effects associated with hormone therapy use. However, compared with cardiovascular diseases and breast cancer, ovarian cancer is far less common, suggesting that overall risk assessment of hormone therapy will not be strongly affected by these results.
The present study did not evaluate dose, and median year of diagnosis was 2001 — slightly before the widespread change in use patterns occurred with publication of the Women’s Health Initiative findings.
It is still not clear whether the current recommendation to use hormone therapy for the shortest duration possible is appropriate for women who are concerned about an increased risk of ovarian cancer. The current report underlines the importance and limitations of observational data for rare and long-term outcomes, especially for the complex associations between regimen, dose, duration, route of administration, and timing of hormone therapy use with ovarian, breast, and endometrial cancers.
Dr. Nicolas Wentzensen and Dr. Britton Trabert are investigators with the division of cancer epidemiology & genetics at the National Cancer Institute, Bethesda, Md. These comments are taken from their accompanying editorial (Lancet 2015 Feb. 13 [doi:10.1016/ S0140-6736(14)62458-2]). They had no competing interests.
Current, short-term use of hormone replacement therapy led to a 43% increase in risk of serous and endometrioid ovarian cancers, according to a large meta-analysis reported online in the Lancet.
Risk fell after women stopped hormone replacement therapy (HRT), but “remained appreciable” for the next few years, wrote the Collaborative Group on Epidemiological Studies of Ovarian Cancer. And long-term users had an estimated 25% increase in ovarian cancer risk, even a full decade after stopping HRT (relative risk, 1.25; 95% confidence interval, 1.07 to 1.46; P = .005), the group reported.
The findings “strongly suggest a causal relationship – i.e., that among otherwise similar women, use of hormone therapy increases the probability of developing the two most common types of ovarian cancer,” the group wrote (Lancet 2015 Feb. 13 [doi: 10.1016/ S0140-6736(14)61687-1]).
Guidelines on HRT from the United States and Europe do not mention ovarian cancer, and those from the United Kingdom describe only risk with long-term use. The findings are “directly relevant to medical advice, personal choices, and the current efforts to revise ... guidelines,” the investigators wrote.
The meta-analysis included 52 observational cohort studies, 17 of which were prospective. In all, 12,110 postmenopausal women in the prospective studies developed ovarian cancer, and 55% had used HRT. Women who had been on HRT for less than 5 years were 1.43 times more likely to develop ovarian cancer than were nonusers (RR, 1.43; 95% CI, 1.29 to 1.46; P < .0001). Thus, HRT might cause one extra case of ovarian cancer per 1,000 users, and one extra death from ovarian cancer per 1,700 users, the group wrote.
Risk of ovarian cancer was similar regardless of age and type of HRT use, the investigators said.
The Medical Research Council and Cancer Research UK funded the analysis. The authors declared no relevant financial conflicts of interest.
Current, short-term use of hormone replacement therapy led to a 43% increase in risk of serous and endometrioid ovarian cancers, according to a large meta-analysis reported online in the Lancet.
Risk fell after women stopped hormone replacement therapy (HRT), but “remained appreciable” for the next few years, wrote the Collaborative Group on Epidemiological Studies of Ovarian Cancer. And long-term users had an estimated 25% increase in ovarian cancer risk, even a full decade after stopping HRT (relative risk, 1.25; 95% confidence interval, 1.07 to 1.46; P = .005), the group reported.
The findings “strongly suggest a causal relationship – i.e., that among otherwise similar women, use of hormone therapy increases the probability of developing the two most common types of ovarian cancer,” the group wrote (Lancet 2015 Feb. 13 [doi: 10.1016/ S0140-6736(14)61687-1]).
Guidelines on HRT from the United States and Europe do not mention ovarian cancer, and those from the United Kingdom describe only risk with long-term use. The findings are “directly relevant to medical advice, personal choices, and the current efforts to revise ... guidelines,” the investigators wrote.
The meta-analysis included 52 observational cohort studies, 17 of which were prospective. In all, 12,110 postmenopausal women in the prospective studies developed ovarian cancer, and 55% had used HRT. Women who had been on HRT for less than 5 years were 1.43 times more likely to develop ovarian cancer than were nonusers (RR, 1.43; 95% CI, 1.29 to 1.46; P < .0001). Thus, HRT might cause one extra case of ovarian cancer per 1,000 users, and one extra death from ovarian cancer per 1,700 users, the group wrote.
Risk of ovarian cancer was similar regardless of age and type of HRT use, the investigators said.
The Medical Research Council and Cancer Research UK funded the analysis. The authors declared no relevant financial conflicts of interest.
Key clinical point: Hormone replacement therapy (HRT) was linked to an increased risk of ovarian cancer.
Major finding: Current use of HRT for less than 5 years was associated with a 43% increase in ovarian cancer risk (P < .0001).
Data source: Meta-analysis of data from 17 prospective studies.
Disclosures: The Medical Research Council and Cancer Research UK funded the study. The authors declared no relevant financial conflicts of interest.